Basilea Pharmaceutica stock

BSLN · SIX · CHF

Compare Basilea Pharmaceutica
CHF 72.80Change from previous close: +0.14%Absolute change: +CHF 0.10

Close · November 20, 2026

Price history

+52.46% over the period

1 year: from CHF 47.75 (November 20, 2025) to CHF 72.80 (November 20, 2026), +52.46%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026CHF 72.80
October 30, 2026CHF 70.80
September 30, 2026CHF 69.90
August 31, 2026CHF 63.50
July 31, 2026CHF 51.90
June 30, 2026CHF 53.40
May 29, 2026CHF 52.10
April 30, 2026CHF 54.40
March 31, 2026CHF 54.40
February 27, 2026CHF 55.20
January 30, 2026CHF 54.00
December 30, 2025CHF 54.70
November 28, 2025CHF 49.05
November 20, 2025CHF 47.75

At a glance

  • The company

    Swiss biotech company developing and commercializing treatments for severe bacterial and fungal infections

  • Latest results

    Quarter to June 30, 2026 · EPS CHF 2.12 (estimate CHF 3.34)

TickerLandia's take on Basilea Pharmaceutica

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 46.40
52-wk highCHF 75.80

−3.96% from the 52-week high

Analysts · 4 analysts

Average targetCHF 99.62+36.84% vs. price

Buy 3 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: Basilea Pharmaceutica

Compared with similar companies: very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Basilea Pharmaceutica is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Basilea Pharmaceutica's P/E today is 23.2, below the median of its last 4 fiscal years (29.2; between 7.10 and 44.9 from 2022 to 2025). Basilea Pharmaceutica's P/E (trailing 12 months): 18.1, +23% against the median of a group of 7 similar companies (14.7).

P/E compared with its history

Compared with 7 similar companies

Basilea Pharmaceutica's metrics compared with similar companies
MetricBasilea PharmaceuticaPosition in the groupBand
P/E (trailing 12 months)18.1Middle
Forward P/E12.6Low
Operating margin24.2%Middle
ROE39.5%High
Debt/equity0.51High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Basilea Pharmaceutica. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

CHF 119M

Latest quarter · Q2 2026

Net income

CHF 27.95M

Latest quarter · Q2 2026

Quarterly net margin

23.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 901.05M
P/E
18.1
EPS
CHF 4.01
Volume
26.18K
Daily trading
€2.73M

How Basilea Pharmaceutica is changing

All results
  • Revenue grew 12.7% a year on average over the last 5 years

  • Operating margin rose from 14.1% to 22.5%

  • Profits turn into cash: free cash flow equal to 113% of net income

Returns

Basilea Pharmaceutica returns with dividends

CHF 1,000 invested in Basilea Pharmaceutica 5 years ago, on November 22, 2021, would be worth CHF 1,834 today with dividends reinvested: +83.38% in total, +12.91% per year. On price alone it would be CHF 1,834 (+83.38%).

PeriodBasilea PharmaceuticaSMICHF 1,000 becomes
1 month+7.85%+0.65%CHF 1,079
6 months+35.06%+8.75%CHF 1,351
Year to date+33.09%+9.83%CHF 1,331
1 year+52.46%+16.18%CHF 1,525
3 years+102.22%+35.68%CHF 2,022
5 years+83.38%+16.48%CHF 1,834
10 years+0.21%+85.64%CHF 1,002

Over the last 6 months it has done better than 57% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Basilea Pharmaceutica: technical analysis

Basilea Pharmaceutica is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 74.2% below its all-time closing high (CHF 282.25, March 30, 2007).

Trend
Upward
RSI (14 sessions)
58
Between 30 and 70
vs 200-session average
+25.20%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 19, 2026

Support and resistance

Price areas where Basilea Pharmaceutica has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 72.80
  3. SupportCHF 69.93−3.94%3 touches, last on November 6, 2026
  4. SupportCHF 58.10−20.19%2 touches, last on April 15, 2026
  5. SupportCHF 56.13−22.91%4 touches, last on July 10, 2026

Volatility and risk

Over the last year it has moved less than the SMI.

Beta (1 year) vs SMI
0.47
Volatility (60 sessions, annualised)
31.3%
Largest fall in the last year
−16.92%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Basilea Pharmaceutica: seasonality

Average monthly price change over 23 years

+5.5%Jan+0.6%Feb−1.9%Mar−0.8%Apr+2.5%May−1.7%Jun+1.2%Jul+0.2%Aug+1.6%Sep−1.1%Oct−1.1%Nov+2.4%Dec

Over the last 23 years, the strongest month for Basilea Pharmaceutica has been January: +5.48% on average, positive in 13 years out of 22. The weakest has been March: −1.88% on average, positive in 8 years out of 22. November, the current month, has been positive in 9 years out of 22 (−1.11% on average).

Show chart data
MonthAverageMedianPositive years
January+5.48%+8.47%13 of 22
February+0.62%+4.64%14 of 22
March−1.88%−1.88%8 of 22
April−0.76%−2.21%9 of 23
May+2.48%+1.30%13 of 23
June−1.69%−0.36%11 of 23
July+1.17%+1.79%13 of 23
August+0.16%−0.62%10 of 23
September+1.63%+0.76%13 of 23
October−1.09%−3.16%9 of 23
November−1.11%−1.45%9 of 22
December+2.44%+1.16%13 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Basilea Pharmaceutica and its competitors

Anti-infective medicines are the core of Basilea Pharmaceutica AG's business, which develops and sells treatments for serious bacterial and fungal infections. Its marketed products are Cresemba, an antifungal given intravenously or orally, and Zevtera, a ceftobiprole-based antibiotic used for pneumonia, Staphylococcus aureus bacteremia and skin infections. The pipeline includes fosmanogepix, a broad-spectrum antifungal for mold infections, and ceftibuten-ledaborbactam etzadroxil, an oral antibiotic for complicated urinary tract infections.

Headquarters
Allschwil, Switzerland
Employees
200
Founded
2000
Chief executive
David Veitch
Basilea Pharmaceutica and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%
Pharma MarPHM$1.1B21.3%14.7−41.56%
IdorsiaIDIA$1.26B-68.4%—−10.26%
PhilogenPHIL$905.96M79.1%3.67−5.63%
InventivaIVA$890.8M-5,980.9%—−33.75%
Pharming GroupPHARM$841.25M12.8%36.1−2.57%

Same industry or related industries, similar size. Compare Basilea Pharmaceutica with its competitors · Full profile